Fighting cancer takes a team, and our pediatric oncology team at NewYork-Presbyterian Morgan Stanley Children's Hospital and NewYork-Presbyterian Komansky Children's Hospital is made up of internationally recognized specialists who collaborate to provide individualized care for each patient. We provide access to groundbreaking pediatric clinical trials and are the only institution in New York designated by the National Cancer Institute to conduct Phase I pediatric clinical trials — the earliest phase of studies for patients.
Pediatric Oncology (Cancer)
Featured Updates
Results from a new multi-center study, led by oncologists at NewYork-Presbyterian and Weill Cornell Medicine, has described for the first time a key biomarker – absolute lymphocyte count (ALC) – that has the potential to predict therapeutic response to chimeric antigen receptor (CAR) T-cell immunotherapy for patients with relapsed/refractory multiple myeloma. While this FDA-approved treatment is widely used, until now there has not been a way to predict whether B-cell maturation antigen (BCMA) CAR T-cell therapy would elicit a good response.
The Latest
Pediatric Neurology & Neurosurgery
Crossing Specialty Lines for Rare Genetic Neurocutaneous Conditions
